Lavanya Mittal1, Lingqiao Zhang2, Rui Feng3, Victoria P Werth4. 1. Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Dermatology, Perelman School of Medicine, the University of Pennsylvania, Philadelphia, Pennsylvania. 2. Department of Dermatology, Perelman School of Medicine, the University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Biostatistics and Epidemiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 4. Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Dermatology, Perelman School of Medicine, the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: werth@mail.med.upenn.edu.
Abstract
BACKGROUND: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remains debated. OBJECTIVE: We investigated the toxicity risk associated with antimalarials in patients with cutaneous lupus erythematosus and dermatomyositis. METHODS: A total of 532 patients (mean age, 52.29 years; sample composition by sex, 85.15% female vs 14.85% male) were selected from 2 databases on cutaneous lupus erythematosus (69.92%) and dermatomyositis (30.08%). Details regarding treatment and toxicities were extracted and 5 treatment courses were defined (ie, hydroxychloroquine [HCQ], chloroquine [CQ], quinacrine [Q], HCQ-Q combination therapy [HCQ-Q], and CQ-Q combination therapy [CQ-Q]). The hazard ratio for each major toxicity was estimated by using the Cox proportional hazard model to compare the different treatments with HCQ. RESULTS: The most common toxicities included cutaneous eruption, gastrointestinal upset, mucocutaneous dyspigmentation, neurologic toxicity, and retinopathy. The hazards of cutaneous eruption, gastrointestinal upset, and neurologic toxicities were lower with HCQ-Q than with HCQ; however, this may represent selection bias. Although there was increased retinopathy risk with CQ and CQ-Q versus with HCQ, retinopathy was not seen with Q. LIMITATIONS: Retrospective analysis. CONCLUSIONS: With the exception of retinopathy, which was not seen with Q, the risks for other toxicities associated with Q monotherapy or combination treatment were not significantly different from those with HCQ. Published by Elsevier Inc.
BACKGROUND: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remains debated. OBJECTIVE: We investigated the toxicity risk associated with antimalarials in patients with cutaneous lupus erythematosus and dermatomyositis. METHODS: A total of 532 patients (mean age, 52.29 years; sample composition by sex, 85.15% female vs 14.85% male) were selected from 2 databases on cutaneous lupus erythematosus (69.92%) and dermatomyositis (30.08%). Details regarding treatment and toxicities were extracted and 5 treatment courses were defined (ie, hydroxychloroquine [HCQ], chloroquine [CQ], quinacrine [Q], HCQ-Q combination therapy [HCQ-Q], and CQ-Q combination therapy [CQ-Q]). The hazard ratio for each major toxicity was estimated by using the Cox proportional hazard model to compare the different treatments with HCQ. RESULTS: The most common toxicities included cutaneous eruption, gastrointestinal upset, mucocutaneous dyspigmentation, neurologic toxicity, and retinopathy. The hazards of cutaneous eruption, gastrointestinal upset, and neurologic toxicities were lower with HCQ-Q than with HCQ; however, this may represent selection bias. Although there was increased retinopathy risk with CQ and CQ-Q versus with HCQ, retinopathy was not seen with Q. LIMITATIONS: Retrospective analysis. CONCLUSIONS: With the exception of retinopathy, which was not seen with Q, the risks for other toxicities associated with Q monotherapy or combination treatment were not significantly different from those with HCQ. Published by Elsevier Inc.
Entities:
Keywords:
chloroquine; cutaneous lupus erythematosus; dermatomyositis; drug reactions; hydroxychloroquine; quinacrine
Authors: Virgínia Braz da Silva; Marceli Agostinho Sousa; Isabel Cristiane Kuniyoshi; Fernanda Soares Aurélio; André Luiz Lopes Sampaio; Carlos Augusto Costa Pires de Oliveira Journal: Int Tinnitus J Date: 2015
Authors: Michael F Marmor; Ulrich Kellner; Timothy Y Y Lai; Ronald B Melles; William F Mieler Journal: Ophthalmology Date: 2016-03-16 Impact factor: 12.079
Authors: Sophie L Penman; Robyn T Kiy; Rebecca L Jensen; Christopher Beoku-Betts; Ana Alfirevic; David Back; Saye H Khoo; Andrew Owen; Munir Pirmohamed; B Kevin Park; Xiaoli Meng; Christopher E Goldring; Amy E Chadwick Journal: Br J Pharmacol Date: 2020-08-13 Impact factor: 8.739
Authors: Claudia Cristina Biguetti; Joel Ferreira Santiago Junior; Matthew William Fiedler; Mauro Toledo Marrelli; Marco Brotto Journal: Sci Rep Date: 2021-03-23 Impact factor: 4.379
Authors: Srita Chakka; Rebecca L Krain; Josef Symon S Concha; Benjamin F Chong; Joseph F Merola; Victoria P Werth Journal: Ann Transl Med Date: 2021-03
Authors: Adarsh Ravishankar; Daisy Yan; Christina E Bax; Josef S Concha; Rui Feng; Victoria P Werth Journal: J Am Acad Dermatol Date: 2020-07-23 Impact factor: 11.527